Clinical Trials

Small Cell Lung Carcinoma

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

52 enrolled 12 charts

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

38 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03212469 2025-05-08

ABIMMUNE

GastrointestinalHead & NeckThoracic

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT03406650 2025-05-04

SAKK 06/17

61 enrolled

Tumor-Agnostic

Neoplasms

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT02087423 2025-04-27

ATLANTIC

446 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05924880 2025-04-22

TopDouble

Phase 3 Completed

116 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04003246 2025-03-21

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

10 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

140 enrolled 9 charts

Advanced Rare Tumours

NCT03871036 2025-03-06

ICRA

53 enrolled

Carcinoma, Transitional Cell

NCT04230408 2025-02-11

PACIFIC BRAZIL

48 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03518606 2025-01-15

MOVIE

BreastGenitourinaryGynecologicHead & Neck

126 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03509012 2025-01-14

CLOVER

Phase 1 Completed

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04249362 2025-01-10

DUART

102 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT03095274 2025-01-09

DUNE

126 enrolled 18 charts

EndocrineNET

Neuroendocrine Tumors

NCT04078152 2024-12-20

WAVE

Phase 4 Completed

163 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03702179 2024-12-05

IMMUNOPRESERVE

32 enrolled 19 charts

Invasive Bladder Cancer

NCT04449861 2024-11-27

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Phase 3 Completed

166 enrolled 20 charts

Small Cell Lung Carcinoma Extensive Disease

NCT03356860 2024-11-20

B-IMMUNE

57 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

40 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04416633 2024-11-08

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Phase 4 Completed

100 enrolled 11 charts

BreastDermatologicGenitourinaryGynecologicThoracic

Unresectable Non-small Cell Lung Cancer (NSCLC)

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02819596 2024-11-04

CALYPSO

69 enrolled

Carcinoma, Renal Cell

NCT03204812 2024-10-15

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

31 enrolled 12 charts